Patents by Inventor Jonathan B. Grimm

Jonathan B. Grimm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190367736
    Abstract: The present invention is generally directed to the synthesis and use of fluorophores. It is more specifically directed to the synthesis and use of deuterated fluorophores. In one case, the present invention provides a compound of the structure shown in FIG. 44.
    Type: Application
    Filed: May 28, 2019
    Publication date: December 5, 2019
    Inventors: Luke Lavis, Jonathan B. Grimm
  • Patent number: 10495632
    Abstract: The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 3, 2019
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Luke D. Lavis, Jonathan B. Grimm, Jiji Chen, Timothee Lionnet, Zhengjian Zhang, Andrey Revyakin, Joel Slaughter
  • Patent number: 10407399
    Abstract: The presently-disclosed subject matter relates to analyte-activated photolabile compounds. The compounds include the formula: wherein Z includes a maskable molecule; L is selected from a bond, C, C(O), O, alkyl, (O)alkyl, and alkoxy; R1 is selected from H, halogen, alkyl, and acyl; each R2 is independently selected from H, alkyl, aryl, and acyl, and is optionally substituted with one or more heteroatoms independently selected from COOH and COO(alkyl); and R3 is selected from H, alkyl, aryl, halogen, CN, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, CHO, COOH, COO(alkyl), COO(aryl), PO3H2, and SO3H, and is optionally substituted with one or more heteroatoms independently selected from N, O, and S, halogen, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, NO2, CHO, COO, COOH, COO(alkyl), COO(aryl), C(O)NR2, PO3H2, and/or SO3H. Also provided are methods of detecting calcium and treating a subject with the analyte-activated photolabile compounds.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: September 10, 2019
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Luke D. Lavis, Jonathan B. Grimm, Laurel M. Heckman, Eric R. Schreiter
  • Publication number: 20190107534
    Abstract: The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Inventors: Luke D. LAVIS, Jonathan B. GRIMM, Jiji CHEN, Timothee LIONNET, Zhengjian ZHANG, Andrey REVYAKIN, Joel SLAUGHTER
  • Publication number: 20190106573
    Abstract: Provided are a photoactive fluorophore, a photoactive ligand, and a photoactive complex. The photoactive fluorophore includes a photoactivatable derivative of an azetidine-containing Janelia-Fluor dye. The photoactive ligand includes a photoactive fluorophore and a protein tag. The photoactive complex includes a photoactive ligand conjugated to a protein. Also provided are methods of in vivo labeling with and photoactivation of the photoactive fluorophore, ligand, and complex.
    Type: Application
    Filed: May 22, 2017
    Publication date: April 11, 2019
    Inventors: Luke D. LAVIS, Jonathan B. GRIMM
  • Patent number: 10161932
    Abstract: The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: December 25, 2018
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Luke D. Lavis, Jonathan B. Grimm, Jiji Chen, Timothee Lionnet, Zhengjian Zhang, Andrey Revyakin, Joel Slaughter
  • Publication number: 20180284105
    Abstract: The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.
    Type: Application
    Filed: June 5, 2018
    Publication date: October 4, 2018
    Inventors: Luke D. LAVIS, Jonathan B. GRIMM, Jiji CHEN, Timothee LIONNET, Zhengjian ZHANG, Andrey REVYAKIN, Joel SLAUGHTER
  • Publication number: 20180251441
    Abstract: The presently-disclosed subject matter relates to analyte-activated photolabile compounds. The compounds include the formula: wherein Z includes a maskable molecule; L is selected from a bond, C, C(O), O, alkyl, (O)alkyl, and alkoxy; R1 is selected from H, halogen, alkyl, and acyl; each R2 is independently selected from H, alkyl, aryl, and acyl, and is optionally substituted with one or more heteroatoms independently selected from COOH and COO(alkyl); and R3 is selected from H, alkyl, aryl, halogen, CN, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, CHO, COOH, COO(alkyl), COO(aryl), PO3H2, and SO3H, and is optionally substituted with one or more heteroatoms independently selected from N, O, and S, halogen, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, NO2, CHO, COO, COOH, COO(alkyl), COO(aryl), C(O)NR2, PO3H2, and/or SO3H. Also provided are methods of detecting calcium and treating a subject with the analyte-activated photolabile compounds.
    Type: Application
    Filed: September 1, 2016
    Publication date: September 6, 2018
    Inventors: Luke D. LAVIS, Jonathan B. GRIMM, Laurel M. HECKMAN, Eric R. SCHREITER
  • Patent number: 10018624
    Abstract: The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: July 10, 2018
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Luke D. Lavis, Jonathan B. Grimm, Jiji Chen, Timothee Lionnet, Zhengjian Zhang, Andrey Revyakin, Joel Slaughter
  • Publication number: 20180172677
    Abstract: The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 21, 2018
    Inventors: Luke D. LAVIS, Jonathan B. GRIMM, Jiji CHEN, Timothee LIONNET, Zhengjian ZHANG, Andrey REVYAKIN, Joel SLAUGHTER
  • Patent number: 9933417
    Abstract: The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: April 3, 2018
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Luke D. Lavis, Jonathan B. Grimm, Jiji Chen, Timothee Lionnet, Zhengjian Zhang, Andrey Revyakin, Joel Slaughter
  • Publication number: 20170045501
    Abstract: The presently-disclosed subject matter includes azetidine-substituted fluorescent compounds, where the compounds may be used as probes, dyes, tags, and the like. The presently-disclosed subject matter also includes kits comprising the same as well as methods for using the same to detect a target substance.
    Type: Application
    Filed: April 1, 2015
    Publication date: February 16, 2017
    Inventors: Luke D. LAVIS, Jonathan B. GRIMM, Jiji CHEN, Timothee LIONNET, Zengjian ZHANG, Audrey REVYAKIN, Joel SLAUGHTER
  • Patent number: 8367706
    Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: February 5, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael Altman, Matthew Christopher, Jonathan B. Grimm, Andrew Haidle, Kaleen Konrad, Jongwon Lim, Rachel N. MacCoss, Michelle Machacek, Ekundayo Osimboni, Ryan D. Otte, Tony Siu, Kerrie Spencer, Brandon Taoka, Paul Tempest, Kevin Wilson, Hyun Chong Woo, Jonathan Young, Anna Zabierek
  • Patent number: 8344144
    Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: January 1, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michelle Machacek, Gabriela de Almeida, Jonathan B. Grimm, Rachel N. MacCoss, Eric Romeo, Tony Siu, Catherine White, Kevin Wilson
  • Patent number: 8168658
    Abstract: The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: May 1, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jonathan B. Grimm, Jed L. Hubbs, Thomas Miller, Karin M. Otte, Phieng Siliphaivanh, Matthew G. Stanton, Kevin Wilson, David Witter, Hua Zhou
  • Publication number: 20110082136
    Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
    Type: Application
    Filed: June 8, 2009
    Publication date: April 7, 2011
    Inventors: Michelle Machacek, Gabriela de Almeida, Jonathan B. Grimm, Rachel N. MacCoss, Eric Romeo, Tony Siu, Catherine White, Kevin Wilson
  • Publication number: 20100256097
    Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
    Type: Application
    Filed: June 16, 2008
    Publication date: October 7, 2010
    Inventors: Michael Altman, Matthew Christopher, Jonathan B. Grimm, Andrew Haidle, Kaleen Konrad, Jongwon Lim, Rachel N. MacCoss, Michelle Machacek, Ekundayo Osimboni, Ryan D. Otte, Tony Siu, Kerrie Spencer, Brandon Taoka, Paul Tempest, Kevin Wilson, Hyan Chong Woo, Jonathan Young, Anna Zabierek
  • Publication number: 20090069250
    Abstract: The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
    Type: Application
    Filed: February 23, 2007
    Publication date: March 12, 2009
    Inventors: Jonathan B. Grimm, Jed L. Hubbs, Thomas Miller, Karin M. Otte, Phieng Siliphaivanh, Matthew G. Stanton, Kevin Wilson, David Witter, Hua Zhou